Gsa Capital Partners LLP Amylyx Pharmaceuticals, Inc. Transaction History

Gsa Capital Partners LLP

  • $1.43 Billion
  • Q2 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 03, 2024
SELL
$2.71 - $19.57 $142,342 - $1.03 Million
-52,525 Reduced 39.74%
79,652 $226,000
Q4 2023

Feb 16, 2024
BUY
$12.07 - $18.46 $1.08 Million - $1.66 Million
89,742 Added 211.48%
132,177 $1.95 Million
Q3 2023

Nov 15, 2023
BUY
$18.08 - $23.45 $514,032 - $666,706
28,431 Added 203.02%
42,435 $776,000
Q2 2023

Aug 14, 2023
BUY
$20.98 - $31.42 $123,677 - $185,220
5,895 Added 72.7%
14,004 $302,000
Q1 2023

May 12, 2023
BUY
$27.71 - $40.93 $224,700 - $331,901
8,109 New
8,109 $237,000

Others Institutions Holding AMLX

# of Institutions
139
Shares Held
46.5M
Call Options Held
226K
Put Options Held
909K
View Full List

About Amylyx Pharmaceuticals, Inc.

AMLX Quotes by TradingView
  • Ticker AMLX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,533,200
  • Market Cap $290M
  • Description
  • Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...
More about AMLX
Track This Portfolio

Track Gsa Capital Partners LLP Portfolio

Follow Gsa Capital Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email